Research programme: antibody-drug conjugates - Ambrx/MabSpace Biosciences

Drug Profile

Research programme: antibody-drug conjugates - Ambrx/MabSpace Biosciences

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Ambrx; MabSpace Biosciences
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 05 Jan 2017 Early research in Cancer in China (unspecified route)
  • 05 Jan 2017 MabSpace Biosciences and Ambrx enter research collaboartion to develop antibody-drug conjugates for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top